Susanne Fuessel Selected Research

Therapeutics

4/2022	Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.
1/2022	Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer.
9/2021	Increased Sensitivity of Detection of RASSF1A and GSTP1 DNA Fragments in Serum of Prostate Cancer Patients: Optimisation of Diagnostics Using OBBPA-ddPCR.
1/2020	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
11/2017	An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
1/2017	Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation.
11/2015	Development of novel radiochemotherapy approaches targeting prostate tumor progenitor cells using nanohybrids.
9/2015	Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells.
4/2015	Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells.
2/2015	Characterization of different carbon nanotubes for the development of a mucoadhesive drug delivery system for intravesical treatment of bladder cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susanne Fuessel Research Topics

Disease

46	Neoplasms (Cancer) 04/2022 - 07/2003
31	Prostatic Neoplasms (Prostate Cancer) 06/2022 - 07/2003
25	Urinary Bladder Neoplasms (Bladder Cancer) 05/2020 - 09/2003
10	Renal Cell Carcinoma (Grawitz Tumor) 06/2016 - 07/2008
6	Carcinoma (Carcinomatosis) 02/2015 - 06/2004
5	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2009
4	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 09/2021 - 06/2012
2	Carcinogenesis 02/2014 - 09/2003
2	Inflammation (Inflammations) 12/2013 - 06/2012
2	Breast Neoplasms (Breast Cancer) 09/2008 - 11/2005
2	Transitional Cell Carcinoma 12/2004 - 11/2004
1	Adenocarcinoma 01/2020
1	Non-Muscle Invasive Bladder Neoplasms 11/2017
1	Disease Progression 11/2016
1	Multiple Myeloma 09/2014

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 11/2016 - 09/2004
11	SurvivinIBA 02/2016 - 06/2004
10	Biomarkers (Surrogate Marker)IBA 09/2021 - 06/2012
9	Messenger RNA (mRNA)IBA 01/2014 - 07/2003
7	Small Interfering RNA (siRNA)IBA 09/2015 - 10/2004
6	Cisplatin (Platino)FDA LinkGeneric 06/2022 - 11/2004
6	MicroRNAs (MicroRNA)IBA 08/2020 - 02/2014
6	OligodeoxyribonucleotidesIBA 05/2008 - 09/2003
5	DNA (Deoxyribonucleic Acid)IBA 09/2021 - 06/2004
5	Telomerase (Telomerase Reverse Transcriptase)IBA 05/2008 - 09/2003
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 04/2022 - 09/2008
4	Carbon Nanotubes (Carbon Nanotube)IBA 01/2017 - 03/2014
4	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2017 - 11/2004
3	PlatinumIBA 06/2022 - 03/2014
3	Neuropilin-2IBA 01/2022 - 01/2019
3	CateninsIBA 11/2017 - 04/2015
3	CarbonIBA 01/2017 - 03/2014
3	AntigensIBA 12/2013 - 06/2006
2	Docetaxel (Taxotere)FDA Link 06/2022 - 01/2017
2	enzalutamideIBA 01/2022 - 01/2020
2	Cell-Free Nucleic AcidsIBA 09/2021 - 02/2019
2	Tumor Biomarkers (Tumor Markers)IBA 08/2020 - 07/2003
2	RNA (Ribonucleic Acid)IBA 01/2020 - 09/2008
2	AndrogensIBA 01/2020 - 09/2005
2	Transcription Factors (Transcription Factor)IBA 11/2017 - 11/2015
2	Keratin-20 (Cytokeratin 20)IBA 09/2017 - 02/2016
2	Sunitinib (Sutent)FDA Link 06/2016 - 01/2013
2	Tyrosine Kinase InhibitorsIBA 06/2016 - 01/2013
2	Aldehyde DehydrogenaseIBA 11/2015 - 04/2015
2	Complementary DNA (cDNA)IBA 03/2015 - 09/2004
2	Plasminogen Activator Inhibitor 1IBA 12/2014 - 06/2013
2	Carboplatin (JM8)FDA LinkGeneric 10/2014 - 03/2014
2	Prostate-Specific Antigen (Semenogelase)IBA 06/2012 - 06/2006
2	EnzymesIBA 06/2012 - 12/2004
2	Peptide Hydrolases (Proteases)FDA Link 04/2010 - 11/2005
2	Keratins (Keratin)IBA 08/2009 - 12/2004
2	Keratin-8 (Keratin 8)IBA 08/2009 - 12/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2008 - 07/2005
2	Nucleic AcidsIBA 02/2007 - 01/2007
2	prosteinIBA 10/2006 - 06/2006
2	Hormones (Hormone)IBA 06/2006 - 06/2004
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 05/2006 - 09/2004
2	Gemcitabine FDA Link 07/2005 - 11/2004
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	NeuropilinsIBA 01/2020
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2019
1	Wnt ReceptorsIBA 06/2018
1	ErbB Receptors (EGF Receptor)IBA 11/2017
1	LuciferasesIBA 11/2017
1	Lysine (L-Lysine)FDA Link 11/2017
1	TrypsinIBA 11/2017
1	alpha-methylacyl-CoA racemaseIBA 11/2017
1	Insulin-Like PeptidesIBA 09/2017
1	MidkineIBA 11/2016
1	Enhancer of Zeste Homolog 2 ProteinIBA 11/2016
1	Pharmaceutical PreparationsIBA 06/2016
1	Catechin (Z 7300)IBA 11/2015
1	TeaIBA 11/2015
1	Galectin 3 (LGALS3)IBA 01/2015
1	prostatic acid phosphataseIBA 01/2015
1	VinculinIBA 01/2015
1	Tissue ExtractsIBA 12/2014
1	EphA2 ReceptorIBA 01/2014
1	EphA1 Receptor (Eph Receptor)IBA 01/2014
1	Biological ProductsIBA 01/2014
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2014
1	AgglutininsIBA 01/2014
1	LigandsIBA 01/2014
1	Phosphotransferases (Kinase)IBA 01/2014
1	Ephrin-A1 (Ephrin A1)IBA 01/2014
1	EphrinsIBA 01/2014
1	Tyrosine (L-Tyrosine)FDA Link 01/2014
1	Plasminogen Activators (Plasminogen Activator)IBA 06/2013

Therapy/Procedure

19	Therapeutics 04/2022 - 06/2004
7	Drug Therapy (Chemotherapy) 06/2022 - 06/2004
3	Castration 06/2022 - 01/2020
2	Radiotherapy 11/2015 - 04/2015
2	Nephrectomy 12/2014 - 07/2009
2	Prostatectomy (Retropubic Prostatectomy) 02/2014 - 10/2006
2	Immunotherapy 06/2006 - 09/2004
1	Treatment Delay 03/2019
1	Precision Medicine 11/2017
1	Catheters 11/2017
1	Chemoradiotherapy 11/2015